Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09TGO
|
|||
| Drug Name |
Autologous ET1402L1-CART cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1 | [1] | |
| Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 1 | [1] | ||
| Metastatic liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 1 | [1] | ||
| Company |
Aeon Therapeutics (Shanghai) Co., Ltd.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HLA-A02/AFP complex (HLA-A02/AFP) | Target Info | CAR-T-Cell-Therapy | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03349255) Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.